Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback